Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

343 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Doravirine/Lamivudine/Tenofovir Disoproxil Fumarate (TDF) Versus Efavirenz/Emtricitabine/TDF in Treatment-naive Adults With Human Immunodeficiency Virus Type 1 Infection: Week 96 Results of the Randomized, Double-blind, Phase 3 DRIVE-AHEAD Noninferiority Trial.
Orkin C, Squires KE, Molina JM, Sax PE, Sussmann O, Lin G, Kumar S, Hanna GJ, Hwang C, Martin E, Teppler H. Orkin C, et al. Clin Infect Dis. 2021 Jul 1;73(1):33-42. doi: 10.1093/cid/ciaa822. Clin Infect Dis. 2021. PMID: 33336698 Free PMC article. Clinical Trial.
A randomized comparative trial of continued zidovudine/lamivudine or replacement with tenofovir disoproxil fumarate/emtricitabine in efavirenz-treated HIV-1-infected individuals.
Fisher M, Moyle GJ, Shahmanesh M, Orkin C, Kingston M, Wilkins E, Ewan J, Liu H, Ebrahimi R, Reilly G; SWEET (Simplification With Easier Emtricitabine Tenofovir) group UK. Fisher M, et al. Among authors: orkin c. J Acquir Immune Defic Syndr. 2009 Aug 15;51(5):562-8. doi: 10.1097/QAI.0b013e3181ae2eb9. J Acquir Immune Defic Syndr. 2009. PMID: 19561519 Clinical Trial.
Virological response to initial antiretroviral regimens containing abacavir or tenofovir.
Bansi L, Sabin C, Gilson R, Gazzard B, Leen C, Anderson J, Dunn D, Hill T, Fisher M, Ainsworth J, Pillay D, Johnson M, Walsh J, Orkin C, Easterbrook P, Gompels M, Phillips A; UK Collaborative HIV Cohort Study. Bansi L, et al. Among authors: orkin c. J Infect Dis. 2009 Sep 1;200(5):710-4. doi: 10.1086/605024. J Infect Dis. 2009. PMID: 19635022
Comparison of changes in bone density and turnover with abacavir-lamivudine versus tenofovir-emtricitabine in HIV-infected adults: 48-week results from the ASSERT study.
Stellbrink HJ, Orkin C, Arribas JR, Compston J, Gerstoft J, Van Wijngaerden E, Lazzarin A, Rizzardini G, Sprenger HG, Lambert J, Sture G, Leather D, Hughes S, Zucchi P, Pearce H; ASSERT Study Group. Stellbrink HJ, et al. Among authors: orkin c. Clin Infect Dis. 2010 Oct 15;51(8):963-72. doi: 10.1086/656417. Clin Infect Dis. 2010. PMID: 20828304 Clinical Trial.
Persistence of HIV-1 transmitted drug resistance mutations.
Castro H, Pillay D, Cane P, Asboe D, Cambiano V, Phillips A, Dunn DT; UK Collaborative Group on HIV Drug Resistance. Castro H, et al. J Infect Dis. 2013 Nov 1;208(9):1459-63. doi: 10.1093/infdis/jit345. Epub 2013 Jul 31. J Infect Dis. 2013. PMID: 23904291 Free PMC article.
Incomplete reversibility of estimated glomerular filtration rate decline following tenofovir disoproxil fumarate exposure.
Jose S, Hamzah L, Campbell LJ, Hill T, Fisher M, Leen C, Gilson R, Walsh J, Nelson M, Hay P, Johnson M, Chadwick D, Nitsch D, Jones R, Sabin CA, Post FA; UK Collaborative HIV Cohort Study Steering Committee. Jose S, et al. J Infect Dis. 2014 Aug 1;210(3):363-73. doi: 10.1093/infdis/jiu107. Epub 2014 Feb 28. J Infect Dis. 2014. PMID: 24585896 Free PMC article.
343 results